Additionally, mutations in CARD11 and TNFAIP3, which operate downstream of BTK, have been identified as potential sources of resistance to ibrutinib in both systemic lymphoma (74) and PCNSL treated with ibrutinib monotherapy (3). The gene discussed is BTK; the disease is primary central nervous system lymphoma.